4.5 Article

Cognitive decline and quality of life in incident Parkinson's disease: The role of attention

Journal

PARKINSONISM & RELATED DISORDERS
Volume 27, Issue -, Pages 47-53

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2016.04.009

Keywords

Parkinson's disease; Quality of life; Mild cognitive impairment; Dementia; Attention

Funding

  1. Parkinson's UK [J-0802]
  2. Lockhart Parkinson's Disease Research Fund
  3. National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University
  4. NIHR Biomedical Research Centre
  5. Biomedical Research Unit, Newcastle University
  6. Michael J. Fox Foundation (MJFF)
  7. Teva-Lundbeck
  8. UCB
  9. GlaxoSmithKline (GSK)
  10. Genus
  11. Britannia Pharmaceuticals Ltd.
  12. AbbVie
  13. UCB Pharma
  14. Movement Disorder Society
  15. Academy of Medical Sciences
  16. Rosetrees Trust
  17. Stevenage Biosciences Catalyst
  18. Addenbrooke's Charitable Trust
  19. NIHR
  20. Parkinson's UK
  21. Cure Parkinson's Trust
  22. MRC
  23. ACT
  24. EU
  25. GE Healthcare
  26. Flynn pharmaceuticals
  27. Wellcome Trust
  28. Acadia Pharmaceuticals
  29. Wellcome Trust [103838/Z/14/Z] Funding Source: Wellcome Trust
  30. MRC [MC_U105597119] Funding Source: UKRI
  31. Medical Research Council [MC_U105597119] Funding Source: researchfish
  32. Parkinson's UK [J-0802] Funding Source: researchfish
  33. Wellcome Trust [103838/Z/14/Z] Funding Source: researchfish

Ask authors/readers for more resources

Introduction: Parkinson's disease dementia (PDD) is associated with poorer quality of life (QoL). Prior to the onset of PDD, many patients experience progressive cognitive impairment. There is a paucity of longitudinal studies investigating the effects of cognitive decline on QoL. This study aimed to determine the longitudinal impact of cognitive change on QoL in an incident PD cohort. Methods: Recently diagnosed patients with PD (n = 212) completed a schedule of neuropsychological assessments and QoL measures; these were repeated after 18 (n = 190) and 36 months (n = 158). Mild cognitive impairment (PD-MCI) was classified with reference to the Movement Disorder Society criteria. Principal component analysis was used to reduce 10 neuropsychological tests to three cognitive factors: attention, memory/executive function, and global cognition. Results: Baseline PD-MCI was a significant contributor to QoL (beta = 0.2, p < 0.01). For those subjects (9%) who developed dementia, cognitive function had a much greater impact on QoL (beta = 10.3, p < 0.05). Multivariate modelling showed attentional deficits had the strongest predictive power (beta =-23, p < 0.01); brief global tests only modestly predicted decline in QoL (beta = 0.4, p < 0.01). Conclusions: PO,MCI was associated with poorer QoL over three years follow up. Cognitive impairment had a greater impact on QoL in individuals who developed dementia over follow-up. Impaired attention was a significant determinant of QoL in PD. Interventions which improve concentration and attention in those with PD could potentially improve QoL. (C) 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC. BY license (http://creativecommons.org/licenses/by/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available